Metformin Hydrochloride SR & Glimepiride Tablets IP

Product Description

Metformin Hydrochloride SR & Glimepiride Tablets IP is a combination of two oral antihyperglycemic agents used in the management of type 2 diabetes mellitus, particularly when diet, exercise, and monotherapy with a single agent do not result in adequate glycemic control.

• Metformin Hydrochloride (Sustained Release) belongs to the biguanide class of antidiabetic drugs. It acts primarily by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. The sustained-release formulation allows for prolonged drug action and improved gastrointestinal tolerability.

• Glimepiride is a second-generation sulfonylurea that stimulates insulin release from functioning pancreatic beta cells. It also exhibits extrapancreatic activity, including enhanced insulin sensitivity at peripheral target sites.

This fixed-dose combination provides a complementary mechanism of action to effectively lower blood glucose levels, reduce insulin resistance, and improve beta-cell responsiveness. It is intended for use as an adjunct to diet and exercise in patients with type 2 diabetes mellitus.